AlloVir

Industry · 11 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving S Adenovirus Infection	Phase 3	2022-04-26
Terminated	Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic C Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections	Phase 2 / Phase 3	2022-03-24
Terminated	Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transp Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection	Phase 1 / Phase 2	2022-03-21
Completed	Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia BK Virus Nephropathy, BK Virus Infection	Phase 2	2021-03-22
Terminated	Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) BK Virus Infection, Hemorrhagic Cystitis	Phase 3	2021-03-18
Completed	Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections	Phase 2 / Phase 3	2021-01-15
Withdrawn	Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B) BK Virus Infection	Phase 1	2018-03-01
Withdrawn	Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) Adenovirus Infection	Phase 1	2017-12-07
Completed	Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) CMV Infections	Phase 1	2015-09-01
Completed	Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant Infection	N/A	2014-06-01
Completed	ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & Viral Infection	Phase 1 / Phase 2	2012-09-01